|
Video: What is a Stock Split?
|
|
Verrica Pharmaceuticals is a dermatology therapeutics company developing medications for skin diseases requiring medical intervention. Co.'s product pipeline consists of: VP-102, which is a propriety drug-device combination that contains a good manufacturing practices-controlled formulation of cantharidin which is being developed for potential use in treating molluscum contagiosum, external genital warts and common warts; VP-315, which is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma; and VP-103, which is a cantharidin based drug device combination for the potential treatment of plantar warts. According to our Verrica Pharmaceuticals stock split history records, Verrica Pharmaceuticals has had 0 splits. | |
|
Verrica Pharmaceuticals (VRCA) has 0 splits in our Verrica Pharmaceuticals stock split history database.
Looking at the Verrica Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Verrica Pharmaceuticals shares, starting with a $10,000 purchase of VRCA, presented on a split-history-adjusted basis factoring in the complete Verrica Pharmaceuticals stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
06/18/2018 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$18.50 |
|
End price/share: |
$6.87 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-62.86% |
|
Average Annual Total Return: |
-15.55% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$3,714.10 |
|
Years: |
5.86 |
|
|
|
|
|